for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biomerica, Inc.

BMRA.O

Latest Trade

3.70USD

Change

-0.05(-1.33%)

Volume

212,116

Today's Range

3.65

 - 

3.86

52 Week Range

3.30

 - 

9.74

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.75
Open
3.66
Volume
212,116
3M AVG Volume
6.67
Today's High
3.86
Today's Low
3.65
52 Week High
9.74
52 Week Low
3.30
Shares Out (MIL)
12.30
Market Cap (MIL)
46.13
Forward P/E
-7.55
Dividend (Yield %)
--

Next Event

Q4 2021 Biomerica Inc Earnings Release

Latest Developments

More

Biomerica Reports 208% Increase In Q3 2021 Sales Over Q3 2020

Biomerica Reports Q1 Sales Of $1.14 Mln

Biomerica Announces Retirement Of Chief Financial Officer, Hiring Of New CFO And Appointment Of New Member To The Board Of Directors

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biomerica, Inc.

Biomerica, Inc. is a biomedical company, which develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The medical diagnostic products are sold in two markets: clinical laboratories and point of care. The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations. Biomerica has developed a diagnostic guided therapy that is designed to allow physicians to identify patient-specific foods, that when removed from the diet, may alleviate or improve an individual's symptoms of Irritable Bowel Syndrome (IBS). This product is called InFoods IBS.

Industry

Medical Equipment & Supplies

Contact Info

17571 von Karman Ave

IRVINE, CA

92614-6207

United States

+1.949.6452111

http://www.biomerica.com/

Executive Leadership

Zackary S. Irani

Chairman of the Board, Chief Executive Officer

Allen C. Barbieri

Lead Independent Executive Vice Chairman of the Board, Corporate Secretary

Steven Sloan

Chief Financial Officer

Francis R. Cano

Independent Director

Catherine Coste

Independent Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.170

2019

-0.260

2020

-0.230

2021(E)

-0.423
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.20
Price To Book (MRQ)
4.35
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-59.67
Return on Equity (TTM)
-50.65

Latest News

Latest News

BRIEF-Biomerica Files For FDA Emergency Use Authorization Of Unique Laboratory Antibody Test For Covid-19

* BIOMERICA FILES FOR FDA EMERGENCY USE AUTHORIZATION (EUA) OF ITS UNIQUE LABORATORY ANTIBODY TEST FOR COVID-19

BRIEF-Mayo Clinic Joins Biomerica's InFoods Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial

* MAYO CLINIC JOINS BIOMERICA’S INFOODS® IRRITABLE BOWEL SYNDROME ("IBS") DIAGNOSTIC-GUIDED THERAPY CLINICAL TRIAL

BRIEF-Biomerica Reports Q3 Sales $1.177 Million Versus $1.261 Million

* BIOMERICA - ON ELISA TEST FORMAT, BELIEVES ITS PRODUCTION CAPACITY AT CALIFORNIA MANUFACTURING FACILITY WILL BE OVER 3.5 MILLION PATIENT TESTS PER MONTH Source text for Eikon: Further company coverage:

BRIEF-Biomerica Begins Shipping Samples Of 10 Minute Test For Covid-19 Virus Exposure

* BIOMERICA BEGINS SHIPPING SAMPLES OF 10 MINUTE TEST FOR COVID-19 VIRUS EXPOSURE

BRIEF-Palm Management Reports 5.46% Stake In Biomerica As Of Feb 26

* PALM MANAGEMENT (US) LLC REPORTS 5.46% STAKE IN BIOMERICA INC AS OF FEBRUARY 26, 2020 - SEC FILING Source text: (http://bit.ly/2TmhjOE) Further company coverage:

BRIEF-Biomerica Announces $2.0 Mln Investment By Palm Global Small Cap Master Fund

* BIOMERICA ANNOUNCES $2.0 MILLION INVESTMENT BY PALM GLOBAL SMALL CAP MASTER FUND Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up